Clinical trials: Anticoagulant
Anticoagulants Causing Adverse Effects in Therapeutic Use, Atrial Fibrillation
Atrial Fibrillation: Risk and Benefits of Anti-coagulation in the Elderly
This study was designed to assess the effectiveness of oral anticoagulants in elderly patients (>=75 years) with atrial fibrillation.
- Conditions
- Anticoagulants Causing Adverse Effects in Therapeutic Use, Atrial Fibrillation, Frail Elderly Syndrome
- Trial name
- Carebbean-e (NCT03828162)
- Testing
- Anticoagulants
- Volunteers
- 2,943 people
- Sponsor
- Karolinska Institutet
Atrial Fibrillation
Treatment Pattern of NOACs (Non-vitamin K Oral Anticoagulants) in Outpatient Users in Colombian Databases
This population-based descriptive study will characterize first-time users of three NOACs (rivaroxaban, dabigatran and apixaban) in prevention of stroke in non-valvular atrial fibrillation (SPAF) patients and will assess the…
- Trial name
- TREND (NCT03474757)
- Testing
- Data Collection
- Where
- Colombia
- Volunteers
- 10,528 people
- Sponsor
- Bayer
Ischemic Stroke
Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance
The purpose of this study is to determine whether Magnetic Resonance Imaging may predict the risk of Intracerebral Hemorrhage for patients with ischemic stroke who receive indefinite oral anticoagulation
- Trial name
- HERO (NCT02238470)
- Testing
- oral anticoagulants
- Where
- 30 sites in Italy, Spain
- Volunteers
- 1,000 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Stroke, Acute, Atrial Fibrillation
SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF)
The purpose of this study is to determine choice of anticoagulant therapy during acute and chronic stages of ischemic stroke/TIA and short- and long-term outcomes, including stroke recurrence and bleeding complications, in…
- Trial name
- SAMURAI-NVAF (NCT01581502)
- Testing
- This is an observational study.
- Where
- 16 sites in Japan
- Volunteers
- 1,000 people
- Sponsor
- Ministry of Health, Labour and Welfare, Japan
Peripheral Arterial Disease
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
The purpose of this study is to understand how the drug rivaroxaban improves symptoms associated with peripheral artery disease.
- Trial name
- NCT05009862
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet, Aspirin 81Mg Ec Tab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Vanderbilt University Medical Center
Hypertriglyceridemia
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals
The primary objective of this study is to determine the effect of Epanova® on the pharmacokinetic and anticoagulant activity of warfarin.
- Trial name
- NCT01431690
- Testing
- warfarin, omefas, omega-3-acid ethyl esters
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Extracorporeal Membrane Oxygenation Complication, Anticoagulants and Bleeding Disorders
Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO
This prospective, randomized, controlled pilot trial aims to assess the safety and feasibility of Argatroban as an alternative anticoagulant to unfractionated heparin in patients receiving extracorporeal membrane oxygenation.
- Trial name
- NCT05226442
- Testing
- Argatroban, Unfractionated heparin
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Medical University of Vienna
Mechanical Aortic and/or Mitral Valve Replacement Operation
Patient International Normalised Ratio (INR) Self-Testing Program
The aims of the study are to prove correlation between laboratory and patient self-testing (PST) measurements, estimation of INR variability within a target therapeutic zone and frequency of hemorrhagic and/or thromboembolic…
- Trial name
- NCT00925197
- Testing
- INR self-testing program
- Volunteers
- 206 people
- Sponsor
- University Hospital, Clermont-Ferrand
Anticoagulants, Warfarin
Daily Vitamin K in Patients on Warfarin With Unstable INRs
The purpose of this study is to determine if daily Vitamin K supplementation stabilizes INRs in patients taking warfarin with a history of frequent dose changes or variable INRs.
- Trial name
- NCT00287313
- Testing
- Vitamin K
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of North Carolina, Chapel Hill
Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral)
Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation
Endothermal heat-induced thrombosis (EHIT) is a thrombotic complication specific to endovenous thermal ablation of the great saphenous vein (GSV), for which no prophylactic regimen is standardized.
- Conditions
- Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral), Varicose Veins Leg, Venous Thrombosis
- Trial name
- NCT07699796
- Testing
- Apixaban, Rivaroxaban
- Where
- United States
- Volunteers
- 564 people
- Sponsor
- Heart, Artery, and Vein Center of Fresno
Foot Ankle Injuries, Anticoagulants and Bleeding Disorders
A Prospective Study in Chinese Patients With Lower Extremity Ankle Fracture of Oral Anticoagulants to Prevent Venous Thromboembolism (VTE)
Deep vein Thrombosis (Deep Venous Thrombosis, DVT) and Pulmonary Embolism, Pulmonary Embolism, PE) both collectively known as Venous thromboembolism (VTE) (Venous Thrombus Embolism, VTE), is a common clinical disease, and…
- Conditions
- Foot Ankle Injuries, Anticoagulants and Bleeding Disorders, Venous Thromboembolism
- Trial name
- NCT04128254
- Testing
- Apixaban Oral Tablet
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Retinal Detachment
Anticoagulant and Antiplatelet Agents in Patients Undergoing Vitreoretinal Surgery
Purpose: To establish the prevalence of anticoagulant, aspirin, and clopidogrel use in patients undergoing vitreoretinal surgery, and to compare the outcome of peribulbar anesthesia between users and non-users.
- Trial name
- NCT01020656
- Where
- France
- Volunteers
- 206 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Atrial Fibrillation, Intracerebral Hemorrhage
NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH
To determine the feasibility of a controlled trial examining the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOACs) compared with ASA for stroke prevention in patients with a high-risk of atrial…
- Trial name
- NASPAF-ICH (NCT02998905)
- Testing
- NOAC, Acetylsalicylic Acid
- Where
- 9 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Population Health Research Institute
Anticoagulants
Coordination of Oral Anticoagulant Care at Hospital Discharge
Oral anticoagulants (OACs - warfarin, dabigatran, rivaroxaban, apixaban and edoxaban) are the very top cause of serious drug-related harm.
- Trial name
- COACHeD (NCT02777047)
- Testing
- Anticoagulation Coordinated Care
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Atrial Fibrillation, Prescribing Practices
Supporting Use of AC Through Provider Profiling of Oral AC Therapy for AF
The SUPPORT-AF study aims to improve rates of anticoagulation (AC) in atrial fibrillation (AF) patients by developing and delivering supportive tools and educational materials to providers treating patients with AF.
- Conditions
- Atrial Fibrillation, Prescribing Practices, Anticoagulants
- Trial name
- SUPPORT-AF (NCT03583008)
- Testing
- Anticoagulation (AC) Intervention--Academic Detailing, Anticoagulation (AC) Intervention--Prescribing Practices
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Pulmonary Embolism, Intermediate-high Risk
Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism
Pilot randomized study of the sidlenafil efficacy in combination with oral anticoagulants in the treatment of patients with intermediate-high risk of pulmonary embolism
- Conditions
- Pulmonary Embolism, Intermediate-high Risk, Combination of Oral Anticoagulation Therapy and Sildenafil
- Trial name
- PSCAT (NCT02946944)
- Testing
- Sildenafil/apixaban, apixaban
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Atrial Fibrillation
Study of Clinical and Laboratory Variables Associated With a Direct Oral Anticoagulant Bioassay Higher Among Those Aged Over 75 Years
The objective of this study was to investigate whether there is a link between clinical and biological variables and bioassay high xaban in elderly patients as part of an unscheduled hospitalization.
- Trial name
- AOD-SA (NCT02894450)
- Testing
- blood test
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Nantes University Hospital
Atrial Fibrillation
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
A prospective non-interventional single-centre study aimed to evaluate actual adherence of AF patients using the validated adherence Scale.
- Trial name
- ANTEY (NCT03790917)
- Where
- Russia
- Volunteers
- 201 people
- Sponsor
- National Research Center for Preventive Medicine
Anticoagulant, Pharmacogenetics
Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care
The interdisciplinary collaboration between doctors, nurses and pharmacists, can facilitate the control of patients under treatment with coumarin anticoagulants, increasing their safety and effectiveness.
- Conditions
- Anticoagulant, Pharmacogenetics, Community Pharmacy Services, Drug Utilization Review
- Trial name
- NCT03154489
- Testing
- acenocoumarol, control
- Where
- Spain
- Volunteers
- 204 people
- Sponsor
- Universidad San Jorge
Percutaneous Coronary Intervention
Registry of the Combination of Antiplatelet Agents and Anticoagulant in Atrial Fibrillation Patients With a CHA2DS2VASc Score >1 Undergoing Percutaneous Coronary Interventions
Patients undergoing percutaneous coronary intervention (PCI) with stent implantation and requiring chronic anticoagulation for atrial fibrillation (AF) with a CHA2DS2-VASc >1 are required to receive triple antithrombotic therapy…
- Trial name
- NCT03012906
- Testing
- the prevalence of ischemic events
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique Hopitaux De Marseille